In this study we have shown that AZD0466, a novel dendrimer nanomedicine based on the dual BCL-XL/BCL-2 inhibitor AZD432013,27,28, is as efficacious as Cisplatin in controlling tumor growth and overall mouse survival (as assessed by time to ethical endpoint), and combinations of these drugs leads to further increased benefit. The gene discussed is BCL2; the disease is neoplasm.